REGINfo: Sanofi-Aventis - Pharmacie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
- Remgro
- RICHEMONT
- RMB Holdings
- Sanlam
- Sasol
- Shoprite
- Standard Bank Group
- Tiger Brands
- Vodacom Group
- WOOLWORTHS
> TA 25
Israel - TA 25
- AVNER OIL
- AZRIELI GROUP
- BEZEQ
- DELEK DRILLIN
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- GAZIT GLOBE
- ICL
- IFF
- ISRAEL CORP
- KENON
- LEUMI
- MIGDAL INSURANCE
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- OSEM
- PAZ OIL
- PERRIGO
- POALIM
- STRAUSS GROUP
- TEVA

Europe

COMPANY SEARCH RESULT

$Sanofi-Aventis: Click to view the issuer\'s details$

Last update : 29/03/2019 >View issuer details

2019.08.19 | 17:36 | Share History / Voting Rights and Number of Shares

puce Sanofi: information concerning the total number of voting rights and shares, July 2019 - HTML (w)

2019.08.19 | 17:36 | Share History / Voting Rights and Number of Shares

puce Sanofi : informations relatives au nombre total de droits de vote et d’actions, juillet 2019 - HTML (w)

2019.08.06 | 07:05 | Permanent Information Releases / General Company News

puce Sanofi : Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis - HTML (w)

2019.08.06 | 07:05 | Permanent Information Releases / General Company News

puce Sanofi : Dupixent® (dupilumab) a montré des résultats de phase III positifs dans le traitement de la dermatite atopique sévère de l’enfant âgé de 6 à 11 ans - HTML (w)

2019.08.06 | 07:00 | Permanent Information Releases / General Company News

puce Sanofi : Dupixent® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis - HTML (w)

2019.08.06 | 07:00 | Permanent Information Releases / General Company News

puce Sanofi : Dupixent® (dupilumab) approuvé par la Commission européenne pour traiter la dermatite atopique modérée à sévère chez les adolescents - HTML (w)

2019.07.29 | 17:56 | Permanent Information Releases / Notification of availability

puce Sanofi : Online Availability of Sanofi Group’s Half-Year Financial Report for 2019 - HTML (w)

2019.07.29 | 17:56 | Permanent Information Releases / Notification of availability

puce Sanofi : Mise en ligne du rapport financier semestriel 2019 - HTML (w)

2019.07.29 | 07:30 | Permanent Information Releases / Sales and Revenues

puce Sanofi delivered solid growth in Q2 2019 - HTML (w)

2019.07.29 | 07:30 | Permanent Information Releases / Sales and Revenues

puce Sanofi affiche une croissance solide au deuxième trimestre 2019 - HTML (w)

2019.07.26 | 22:05 | Permanent Information Releases / General Company News

puce Sanofi : Sanofi provides update on ZynquistaTM (sotagliflozin) type 2 diabetes Phase 3 program and collaboration with Lexicon - HTML (w)

2019.07.26 | 22:05 | Permanent Information Releases / General Company News

puce Sanofi : Sanofi fournit des informations actualisées sur ZynquistaTM (sotagliflozine) dans le traitement du diabète de type 2 et sa collaboration avec Lexicon - HTML (w)

2019.07.26 | 18:30 | Permanent Information Releases / General Company News

puce Sanofi : Information on the departure conditions of Olivier Brandicourt, Chief Executive Officer - HTML (w)

2019.07.26 | 18:30 | Permanent Information Releases / General Company News

puce Sanofi : Information sur les conditions de départ d’Olivier Brandicourt, Directeur Général - HTML (w)

2019.07.23 | 07:00 | Permanent Information Releases / General Company News

puce Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu® in Flu Care - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 2716